相似文献
1
2020-2021 AMMI Canada guidance on the use of antiviral drugs for influenza in the setting of co-circulation of seasonal influenza and SARS-CoV-2 viruses in Canada.
J Assoc Med Microbiol Infect Dis Can. 2020 Dec 31;5(4):214-222. doi: 10.3138/jammi-2020-11-02. eCollection 2020 Dec.
2
2021-2022 AMMI Canada guidance on the use of antiviral drugs for influenza in the COVID-19 pandemic setting in Canada.
J Assoc Med Microbiol Infect Dis Can. 2022 Feb 24;7(1):1-7. doi: 10.3138/jammi-2022-01-31. eCollection 2022 Mar.
3
Systematic review of influenza resistance to the neuraminidase inhibitors.
BMC Infect Dis. 2011 May 19;11:134. doi: 10.1186/1471-2334-11-134.
4
Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.
Influenza Other Respir Viruses. 2013 Sep;7(5):645-58. doi: 10.1111/irv.12113. Epub 2013 Apr 10.
5
Antivirals for post-exposure prophylaxis of influenza: a systematic review and network meta-analysis.
Lancet. 2024 Aug 24;404(10454):764-772. doi: 10.1016/S0140-6736(24)01357-6.
6
Antiviral susceptibility of SARS-CoV-2 and influenza viruses from 3 co-infected pediatric patients.
Int J Infect Dis. 2024 Sep;146:107134. doi: 10.1016/j.ijid.2024.107134. Epub 2024 Jun 27.
7
Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.
J Infect Chemother. 2012 Dec;18(6):858-64. doi: 10.1007/s10156-012-0428-1. Epub 2012 May 29.
8
Zanamivir-resistant influenza viruses with a novel neuraminidase mutation.
J Virol. 2009 Oct;83(20):10366-73. doi: 10.1128/JVI.01200-09. Epub 2009 Jul 29.
9
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance.
Influenza Other Respir Viruses. 2013 Jan;7 Suppl 1(Suppl 1):25-36. doi: 10.1111/irv.12047.
10
Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
Antiviral Res. 2013 Sep;99(3):261-9. doi: 10.1016/j.antiviral.2013.06.003. Epub 2013 Jun 17.
本文引用的文献
1
Use of antiviral drugs for seasonal influenza: Foundation document for practitioners-Update 2019.
J Assoc Med Microbiol Infect Dis Can. 2019 Jun 17;4(2):60-82. doi: 10.3138/jammi.2019.02.08. eCollection 2019 Jun.
2
The impact of influenza vaccination on the COVID-19 pandemic? Evidence and lessons for public health policies.
Vaccine. 2020 Sep 29;38(42):6485-6486. doi: 10.1016/j.vaccine.2020.08.024. Epub 2020 Aug 19.
3
Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection.
Cochrane Database Syst Rev. 2020 Aug 26;8(8):CD013705. doi: 10.1002/14651858.CD013705.
4
Influenza in the COVID-19 Era.
JAMA. 2020 Oct 6;324(13):1342-1343. doi: 10.1001/jama.2020.14661.
5
Influenza Vaccination: An Ally to Mitigate Influenza-associated Risks During the Coronavirus Disease 2019 (COVID-19) Pandemic.
Clin Infect Dis. 2021 Jun 15;72(12):2249-2250. doi: 10.1093/cid/ciaa1190.
6
Clinical features of COVID-19 and influenza: a comparative study on Nord Franche-Comte cluster.
Microbes Infect. 2020 Oct;22(9):481-488. doi: 10.1016/j.micinf.2020.05.016. Epub 2020 Jun 16.
7
The Need for Robust Epidemiological Evidence During a Pandemic.
Clin Infect Dis. 2020 Nov 19;71(16):2289-2290. doi: 10.1093/cid/ciaa770.
8
Letter to the Editor.
Vaccine. 2020 Jun 19;38(30):4651. doi: 10.1016/j.vaccine.2020.04.016. Epub 2020 May 26.
9
Influenza Vaccine Does Not Increase the Risk of Coronavirus or Other Noninfluenza Respiratory Viruses: Retrospective Analysis From Canada, 2010-2011 to 2016-2017.
Clin Infect Dis. 2020 Nov 19;71(16):2285-2288. doi: 10.1093/cid/ciaa626.
10
Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus 2: A Narrative Review.
Ann Intern Med. 2020 Jun 2;172(11):726-734. doi: 10.7326/M20-1301. Epub 2020 Apr 13.
Zotero 插件